Vaccine hopes for C. diff

A vaccine to combat C. diff has shown promising results in initial trials and researchers hope to test the product in NHS hospitals later this year.

The vaccine, being developed by Acambis, is claimed to combat the toxins produced by the infection. In a trial on 200 patients, the vaccine proved effective on one of the main toxins in 100% of cases and on a second main toxin in 75% of cases. It is hoped that a course of three injections may provide protection for over ten years.

Latest Issues

EBME Expo 2025

Coventry Building Society Arena, UK
25th - 26th June 2025

AfPP Annual National Conference

University of Warwick
8th - 9th August 2025

Clinical Engineering Conference

Stansted Radisson Blu
23rd September 2025

Infection Prevention 2025

Brighton Centre, UK
29th - 30th September 2025